Celldex culls eczema study after Phase 2 failure
Celldex Therapeutics is dropping its monoclonal antibody as a therapy for eczema after the drug flunked a mid-stage study. The drug, called barzolvolimab, failed to reduce itching in patients with eczema compared with placebo after ...
comments(0)
5-min edit window · permanent after that